On February 15, in response to the company’s incomplete disclosure of information and the supervision conversation between the two high-level regulators by Tianjin Securities Regulatory Bureau, a statement provided by the Secretary of Andon Health Co.Ltd(002432) showed that in view of the effectiveness of the company’s kit products in detecting Omicron virus, the company has carefully passed the triple verification of bioinformatics comparison, recombinant N protein test and test performance experiment, Finally, the experimental results were disclosed in the form of announcement. The experiment was the data obtained by NIH, a cooperative organization of FDA, through the live virus experiment. The experimental report involved many professional contents. At that time, the company mainly considered that there were many professional terms involved and did not want to write the announcement too difficult to interpret, so it used a relatively concise statement, The test results of the company’s kit products on Omicron virus are stated, and the original translation and original link of the suggestions and conclusions given by FDA based on this situation are also written in the announcement. The announcement of the company also takes into account that investors can understand the relevant situation through the company’s official information to avoid misinformation, It is based on the perspective of investor protection.
“In 2021, the company issued more than 100 announcements and replied to more than 400 interactive questions. Because of the high attention at that time, the letter Phi should be paid more attention to.” The statement shows that the regulatory authorities pointed out in the announcement that there are deficiencies in the integrity of the letter phi. It is also a normal regulatory work to talk and guide. The company understands, respects and accepts the opinions of the regulatory authorities and will improve it in the future work, “but you don’t have to break it down”.
Andon Health Co.Ltd(002432) on February 14, it was announced that due to the incomplete disclosure of information, Tianjin Securities Regulatory Bureau decided to take supervision and management measures for the chairman and Secretary of the company.
According to the announcement, the company recently received the decision on administrative supervision measures and the decision on taking supervision talk measures against Liu Yi and Wu Tong from Tianjin Securities Regulatory Bureau. According to the decision, on January 7, 2022, Andon Health Co.Ltd(002432) disclosed that on January 5, 2022 Beijing time, the company received the performance test report of the Radx project of the National Institutes of Health (NIH) on the ohealth covid-19 antigen home self-test OTC kit against Omicron variant virus arranged by the FDA, The report also said that “the ihealth-covid-19 antigen rapid test detected 100% of Omicron active virus samples with a maximum CT value of 21.59 (n = 5)”.
On January 15, 2022, when replying to the letter of concern from Shenzhen Stock Exchange, the company said that “100% of Omicron active virus samples with a maximum CT value of 21.59 (n = 5) were detected in the experiment” previously disclosed by the company, in which “maximum” means that samples less than or equal to 21.59 can be detected 100%, and samples greater than 21.59 cannot be detected 100%, It also said that “the positive detection rate of all samples in the experimental group: when the CT value is ≤ 21.59, it can be detected completely, when the CT value is 22.86, it can be detected 60%, and when the CT value is ≥ 23.87, it can not be detected at all.”
According to the decision, Andon Health Co.Ltd(002432) only disclosed some successful test results on January 7, 2022, but did not disclose all the test results, and the disclosure information was incomplete.
